Nitto Avecia

avecia.com

Nitto Avecia
Nitto Avecia is the largest oligonucleotide manufacturer in the world and continues to play an integral role in advancing the oligo therapeutic market.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

EXSCIENTIA TO SCREEN 15,000 DRUGS IN SEARCH FOR CORONAVIRUS TREATMENT

HIT Consultant | April 07, 2020

news image

Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK’s national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus. Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready molecules, and ...

Read More

Business Insights

LABCORP ENHANCES CLINICAL TRIAL AND DRUG DEVELOPMENT CAPABILITIES THROUGH REAL WORLD DATA COLLABORATION WITH HEALTHVERITY

Labcorp® | June 23, 2022

news image

Labcorp® a leading global life sciences company, announced a new collaboration with HealthVerity, Inc., the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data that will expand Labcorp’s comprehensive, end-to-end drug development and clinical trial programs. HealthVerity’s IPGE platform, an integrated technology and RWD infrastructure, enables Labcorp Drug Development and other participating companies to access fully interoperable, HIPA...

Read More

PHARMACY MARKET, PHARMA TECH

SIMULATIONS PLUS ACQUIRES IMMUNETRICS TO EXPAND ITS IMMUNOLOGY AND ONCOLOGY DRUG DEVELOPMENT CAPABILITIES

Businesswire | June 21, 2023

news image

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the acquisition of Immunetrics, Inc. (“Immunetrics”), a modeling and simulation company focused on accelerating drug development in oncology, immunology, and autoimmune diseases, areas that are among the fastest growing therapeutics. Under the terms of the Agreement, Simulations Plus agreed to pay the shareholders of Immun...

Read More

Business Insights

LOVE PHARMAS INVESTMENT IN US BIOTECH OFFERS STRATEGIC INDUSTRY ADVANTAGES AND ENHANCED SHAREHOLDER VALUE

LOVE Pharma | September 09, 2022

news image

Love Pharma Inc. an international mental health and sexual wellness company, remains extremely active in shaping itself into a real competitor in the biotech/pharmaceutical space. The company’s growth and development plan took a major leap forward this week with the announcement that Love Pharma is establishing a “strategic alliance” with Starton Therapeutics a leading clinical-stage biotechnology company in the United States. It’s a relationship that...

Read More
news image

EXSCIENTIA TO SCREEN 15,000 DRUGS IN SEARCH FOR CORONAVIRUS TREATMENT

HIT Consultant | April 07, 2020

Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK’s national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus. Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready molecules, and ...

Read More
news image

Business Insights

LABCORP ENHANCES CLINICAL TRIAL AND DRUG DEVELOPMENT CAPABILITIES THROUGH REAL WORLD DATA COLLABORATION WITH HEALTHVERITY

Labcorp® | June 23, 2022

Labcorp® a leading global life sciences company, announced a new collaboration with HealthVerity, Inc., the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data that will expand Labcorp’s comprehensive, end-to-end drug development and clinical trial programs. HealthVerity’s IPGE platform, an integrated technology and RWD infrastructure, enables Labcorp Drug Development and other participating companies to access fully interoperable, HIPA...

Read More
news image

PHARMACY MARKET, PHARMA TECH

SIMULATIONS PLUS ACQUIRES IMMUNETRICS TO EXPAND ITS IMMUNOLOGY AND ONCOLOGY DRUG DEVELOPMENT CAPABILITIES

Businesswire | June 21, 2023

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the acquisition of Immunetrics, Inc. (“Immunetrics”), a modeling and simulation company focused on accelerating drug development in oncology, immunology, and autoimmune diseases, areas that are among the fastest growing therapeutics. Under the terms of the Agreement, Simulations Plus agreed to pay the shareholders of Immun...

Read More
news image

Business Insights

LOVE PHARMAS INVESTMENT IN US BIOTECH OFFERS STRATEGIC INDUSTRY ADVANTAGES AND ENHANCED SHAREHOLDER VALUE

LOVE Pharma | September 09, 2022

Love Pharma Inc. an international mental health and sexual wellness company, remains extremely active in shaping itself into a real competitor in the biotech/pharmaceutical space. The company’s growth and development plan took a major leap forward this week with the announcement that Love Pharma is establishing a “strategic alliance” with Starton Therapeutics a leading clinical-stage biotechnology company in the United States. It’s a relationship that...

Read More

Resources

resource image

Pharma Tech

ValGenesis e-Logbook

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us